Literature DB >> 22142748

Miscellaneous non-inflammatory musculoskeletal conditions. Blau syndrome.

Leonardo Punzi1, Alessandra Gava, Paola Galozzi, Paolo Sfriso.   

Abstract

Blau syndrome (BS) is a rare dominantly inherited, inflammatory syndrome characterised by the clinical triad of granulomatous dermatitis, symmetric arthritis and recurrent uveitis. The caspase recruitment domain gene CARD15/NOD2 has been identified as the gene responsible for BS. In the majority of patients, the disease is characterised by early onset, usually before 3-4 years of age. Onset is most often articular and cutaneous. Eye symptoms usually start later; however, eye involvement is the most relevant morbidity of BS. Atypical cases of BS have been reported with involvement of organs other than skin, joint and eyes. Due to its rarity and the variations in the severity and evolution of its expressions, there have been no studies on the optimal treatment for patients with BS. If the therapeutic response to corticosteroids is unsatisfactory, additional treatment with immunosuppressive agents should be tried. The results with biologic anti-cytokine agents, such as infliximab and anakinra, are variable, particularly with regard to ocular morbidity. This review will focus on the clinical and genetics aspects of the familial and the sporadic form of BS. Further, we will describe an Italian family followed by us over the past 25 years.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22142748     DOI: 10.1016/j.berh.2011.10.017

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  13 in total

1.  Aberrant interleukin-1 signalling does not increase susceptibility of mice to NOD2-dependent uveitis.

Authors:  Ellen J Lee; Jordan J Allensworth; Jenna S Clowers; Holly L Rosenzweig
Journal:  Clin Exp Ophthalmol       Date:  2014-10-30       Impact factor: 4.207

Review 2.  Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature.

Authors:  Francesco La Torre; Giovanni Lapadula; Luca Cantarini; Orso Maria Lucherini; Florenzo Iannone
Journal:  Clin Rheumatol       Date:  2014-01-21       Impact factor: 2.980

3.  Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice.

Authors:  Jae Dugan; Eric Griffiths; Paige Snow; Holly Rosenzweig; Ellen Lee; Brieanna Brown; Daniel W Carr; Carlos Rose; James Rosenbaum; Michael P Davey
Journal:  J Immunol       Date:  2014-11-26       Impact factor: 5.422

Review 4.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 5.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

6.  Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review.

Authors:  Carmen Álvarez-Reguera; Diana Prieto-Peña; Alba Herrero-Morant; Lara Sánchez-Bilbao; José Luis Martín-Varillas; Elena González-López; María Gutiérrez-Larrañaga; David San Segundo; Rosalía Demetrio-Pablo; Gonzalo Ocejo-Vinyals; Miguel A González-Gay; Ricardo Blanco
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-04-29       Impact factor: 3.625

7.  A new mutation in blau syndrome.

Authors:  Cengiz Zeybek; Gokalp Basbozkurt; Davut Gul; Erkan Demirkaya; Faysal Gok
Journal:  Case Rep Rheumatol       Date:  2015-01-27

8.  Ultrasonographic assessment reveals detailed distribution of synovial inflammation in Blau syndrome.

Authors:  Kei Ikeda; Naotomo Kambe; Syuji Takei; Taiji Nakano; Yuzaburo Inoue; Minako Tomiita; Natsuko Oyake; Takashi Satoh; Tsuyoshi Yamatou; Tomohiro Kubota; Ikuo Okafuji; Nobuo Kanazawa; Ryuta Nishikomori; Naoki Shimojo; Hiroyuki Matsue; Hiroshi Nakajima
Journal:  Arthritis Res Ther       Date:  2014-04-08       Impact factor: 5.156

Review 9.  Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.

Authors:  Giuseppe Lopalco; Luca Cantarini; Antonio Vitale; Florenzo Iannone; Maria Grazia Anelli; Laura Andreozzi; Giovanni Lapadula; Mauro Galeazzi; Donato Rigante
Journal:  Mediators Inflamm       Date:  2015-02-16       Impact factor: 4.711

10.  A case of blau syndrome.

Authors:  Krati Chauhan; Clement Michet
Journal:  Case Rep Rheumatol       Date:  2014-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.